$2.54T
Total marketcap
$192.74B
Total volume
BTC 49.93%     ETH 15.86%
Dominance

AstraZeneca PLC AZNCF Stock

130.91 USD {{ price }} -0.387995% {{change_pct}}%
Exchange
Other OTC
Market Cap
203.38B USD
LOW - HIGH [24H]
130.91 - 133.08 USD
VOLUME [24H]
823 USD
{{ volume }}
P/E Ratio
34.35
Earnings per share
3.81 USD

AstraZeneca PLC Price Chart

AstraZeneca PLC AZNCF Financial and Trading Overview

AstraZeneca PLC stock price 130.91 USD
Previous Close 146.88 USD
Open 148.3 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 148.3 - 149.25 USD
52 Week Range 104.5 - 153.1 USD
Volume 2.97K USD
Avg. Volume 4.8K USD
Market Cap 231.32B USD
Beta (5Y Monthly) 0.194636
PE Ratio (TTM) 48.615635
EPS (TTM) 3.81 USD
Forward Dividend & Yield 2.88 (1.95%)
Ex-Dividend Date February 23, 2023
1y Target Est N/A

AZNCF Valuation Measures

Enterprise Value 257.22B USD
Trailing P/E 48.615635
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 5.2764163
Price/Book (mrq) 6.459641
Enterprise Value/Revenue 5.867
Enterprise Value/EBITDA 17.279

Trading Information

AstraZeneca PLC Stock Price History

Beta (5Y Monthly) 0.194636
52-Week Change 24.14%
S&P500 52-Week Change 20.43%
52 Week High 153.1 USD
52 Week Low 104.5 USD
50-Day Moving Average 147.43 USD
200-Day Moving Average 132.36 USD

AZNCF Share Statistics

Avg. Volume (3 month) 4.8K USD
Avg. Daily Volume (10-Days) 2.84K USD
Shares Outstanding 1.55B
Float 1.54B
Short Ratio N/A
% Held by Insiders 0.23%
% Held by Institutions 50.59%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 2.9
Trailing Annual Dividend Yield 1.97%
5 Year Average Dividend Yield 275.00%
Payout Ratio 0.945
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 10.73%
Operating Margin (ttm) 23.09%
Gross Margin 84.30%
EBITDA Margin 33.95%

Management Effectiveness

Return on Assets (ttm) 6.42%
Return on Equity (ttm) 13.05%

Income Statement

Revenue (ttm) 43.84B USD
Revenue Per Share (ttm) 28.32 USD
Quarterly Revenue Growth (yoy) -4.50%
Gross Profit (ttm) 35.73B USD
EBITDA 14.89B USD
Net Income Avi to Common (ttm) 4.7B USD
Diluted EPS (ttm) 3.07
Quarterly Earnings Growth (yoy) 367.09%

Balance Sheet

Total Cash (mrq) 6.46B USD
Total Cash Per Share (mrq) 4.17 USD
Total Debt (mrq) 32.47B USD
Total Debt/Equity (mrq) 90.68 USD
Current Ratio (mrq) 0.896
Book Value Per Share (mrq) 23.105

Cash Flow Statement

Operating Cash Flow (ttm) 9.71B USD
Levered Free Cash Flow (ttm) 9.69B USD

Profile of AstraZeneca PLC

Country United States
State N/A
City Cambridge
Address 1 Francis Crick Avenue
ZIP CB2 0AA
Phone 44 20 3749 5000
Website https://www.astrazeneca.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 83500

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Q&A For AstraZeneca PLC Stock

What is a current AZNCF stock price?

AstraZeneca PLC AZNCF stock price today per share is 130.91 USD.

How to purchase AstraZeneca PLC stock?

You can buy AZNCF shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for AstraZeneca PLC?

The stock symbol or ticker of AstraZeneca PLC is AZNCF.

Which industry does the AstraZeneca PLC company belong to?

The AstraZeneca PLC industry is Drug Manufacturers-General.

How many shares does AstraZeneca PLC have in circulation?

The max supply of AstraZeneca PLC shares is 1.55B.

What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?

AstraZeneca PLC PE Ratio is 34.35958000 now.

What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?

AstraZeneca PLC EPS is 3.81 USD over the trailing 12 months.

Which sector does the AstraZeneca PLC company belong to?

The AstraZeneca PLC sector is Healthcare.